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FAS system deregulation in T-cell lymphoblastic
lymphoma
M Villa-Morales1,2,3, MA Cobos1,2,3, E Gonza´lez-Gugel4, V A´lvarez-Iglesias5, B Martı´nez2,6, MA Piris7, A Carracedo5,8, J Benı´tez2,9
and J Ferna´ndez-Piqueras*,1,2,3
The acquisition of resistance towards FAS-mediated apoptosis may be required for tumor formation. Tumors from various
histological origins exhibit FAS mutations, the most frequent being hematological malignancies. However, data regarding FAS
mutations or FAS signaling alterations are still lacking in precursor T-cell lymphoblastic lymphomas (T-LBLs). The available data
on acute lymphoblastic leukemia, of precursor origin as well, indicate a low frequency of FAS mutations but often report a
serious reduction in FAS-mediated apoptosis as well as chemoresistance, thus suggesting the occurrence of mechanisms able
to deregulate the FAS signaling pathway, different from FAS mutation. Our aim at this study was to determine whether
FAS-mediated apoptotic signaling is compromised in human T-LBL samples and the mechanisms involved. This study on 26
T-LBL samples confirms that the FAS system is impaired to a wide extent in these tumors, with 57.7% of the cases presenting any
alteration of the pathway. A variety of mechanisms seems to be involved in such alteration, in order of frequency the
downregulation of FAS, the deregulation of other members of the pathway and the occurrence of mutations at FAS. Considering
these results together, it seems plausible to think of a cumulative effect of several alterations in each T-LBL, which in turn may
result in FAS/FASLG system deregulation. Since defective FAS signaling may render the T-LBL tumor cells resistant to apoptotic
cell death, the correct prognosis, diagnosis and thus the success of anticancer therapy may require such an in-depth knowledge
of the complete scenario of FAS-signaling alterations.
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Precursor T-cell lymphoblastic lymphomas (T-LBLs) are
neoplasms derived from immature thymocytes at varying
stages of differentiation.1 T-LBLs are aggressive malignan-
cies that account for about one-third of childhood non-Hodgkin
lymphomas (NHL).2 Small to medium-sized blast cells with
round to irregular or convoluted nuclei and a high mitotic
activity compose T-LBLs. In terms of immunophenotype, they
are characteristically positive for terminal deoxynucleotidyl
transferase (TdT).3 The molecular genetics of T-LBL are
not well characterized, mainly due to the scarcity of samples
for study.
FAS (CD95/APO-1) is a membrane receptor belonging to
the tumor necrosis factor receptor (TNFR) superfamily whose
mature canonical isoform (Ensemble FAS-005) encodes a
type-1 transmembrane (TM) glycoprotein of B48 kDa.4 The
ligand for FAS receptor FASLG (CD95L) belongs to the TNF
superfamily.5 Its canonical isoform (Ensembl FASLG-001)
encodes a type-2 TM protein of 40 kDa. Previously to the
binding of the ligand and independently of this event, FAS
molecules preassociate in homotrimers on the cell surface
through their so-called pre-ligand assembly domain (PLAD).6
The TNF homology domain (THD) in FASLG mediates self-
association into a compact ligand homotrimer that interacts
with FAS through its cysteine-rich domains (CRDs).7 The
ligand-activated receptor trimers recruit the adapter molecule
FAS-associated death domain (FADD) by homotypic interac-
tion through their death domains (DDs). FADD recruits the
initiator procaspase 8 (CASP8) by the death effector domain
(DED) to form the death-inducing signaling complex (DISC).8
Procaspase 8 is cleaved in the DISC to give rise to active
caspase 8, which dissociates from the DISC to proceed with
the activation of the caspase cascade,9 eventually leading to
apoptosis.
Peripheral T-cell homeostasis involves apoptosis mediated
by the FAS system. Moreover, apoptosis during negative/
positive selection of thymocytes inside the thymus is certainly
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not only mediated by the FAS system, but it may participate in
clonal deletion under certain circumstances.10 Undermining
the immune system and suppressing the antitumor response
are essential events during carcinogenesis allowing tumor
formation.11 In this context, the FAS/FASLG system can elicit
both tumorigenic and tumor-suppressing roles in the patho-
genesis of cancer.11 However, FAS and FASLG genes have
been traditionally considered tumor suppressor genes.12 This
is supported by findings showing functional polymorphisms in
Fas and Fasl genes between strains of mice with extremely
different susceptibilities to certain tumors.13–15
A causative relationship between the occurrence of FAS
mutations and cancer has been widely suggested in the
literature. Tumors from various histological origins have been
found to exhibit FAS mutations, the most frequent being,
however, hematological malignancies. Interestingly, hot spots
affecting exons 8 and 9, mainly responsible for the intracel-
lular domain (ICD) of FAS, have been described. Among
them, some mutations are recurrent.16 However, data
regarding FASmutations or FAS signaling alterations are still
lacking in T-LBL. The available data on acute lymphoblastic
leukemia (ALL), of precursor origin as well, indicate a low
frequency of FAS mutations but often report a serious
reduction in FAS-mediated apoptosis as well as chemoresis-
tance,17,18 thus suggesting the occurrence of mechanisms
able to deregulate the FAS signaling pathway, different from
FAS mutation.
Our aim at this study is to determine whether FAS-mediated
apoptotic signaling is compromised in human T-LBL samples
and the mechanism or mechanisms involved in such altera-
tion. As various alterations affecting FAS signalingmay confer
resistance to malignant cells, a better knowledge of this
scenario in T-LBL may become essential for prognosis,
diagnosis and thus the success of therapy.
Results
Mutations affecting FAS in human T-LBL samples. FAS
cDNAs from 26 human T-LBL samples were sequenced. We
found that 5 out of the 26 samples (19.2%) analyzed
exhibited one or two heterozygous mutations at FAS. The
mutations found were spread all along the FAS cDNA
sequence (Figure 1), and none of them had been described
previously in the literature. Among these five samples
exhibiting FAS mutations, two of them (samples 00800-
SD1–1 and 04011685) had the same mutation, whereas the
other three samples had different mutations each other
(Tables 1 and 2). The mutations are defined according to the
recommendations by the Human Genome Variation Society,
last modified in 22 March 2013.19
In sample 000–220, a nucleotide substitution causes a
missense mutation in exon 3, which would affect the CRD2
domain. This sample exhibited a base insertion in exon 9 as
well, which entailed a sequence frameshift responsible for the
incorporation after residue 300 of a sequence of 19 amino
acids not present in the wild-type sequence, together with the
premature termination at codon 320.
In samples 00800-SD1–1 and 04011685, the same base
insertion in exon 4 caused sequence frameshift responsible
for the substitution of cysteine in position 135 to leucine,
together with the premature termination immediately at
codon 136.
In sample 02M-121, a base substitution in exon 2 provoked
a missense mutation at the signal peptide (SP). Interestingly,
this sample showed as well the presence of an alternatively
spliced isoform skipping exon 6, thus lacking the TM domain,
which produces soluble FAS (sFAS) protein.
Sample 20040730 showed a base substitution at exon 4
causing a missense mutation, which affects CRD3.
The predicted damage of each mutation was determined
using the Polyphen-2 software (biobyte solutions GmbH,
Heidelberg, Germany). On the basis of the mutation position,
the software prediction and the literature, it has been
predicted how each FAS mutant variant might behave in
terms of FAS signaling (Table 1). Taken together, our results
indicate that the occurrence of mutations in FAS might be
involved, to a certain extent, in T-LBL in humans.
Mutant FAS variants present with altered in-vitro
expression levels. We cloned each of the four different
mutant FAS variants found among our T-LBL samples in
pKEX vector and examined FAS protein expression after
transfection of JK T cells (Figure 2a), using UB2 anti-FAS
monoclonal antibody, known to target an identical epitope on
the extracellular domain (ECD) of CD95 than CH11 anti-FAS
antibody.20 Flow cytometry showed that JK cells have
endogenous levels of membrane FAS (mFAS) of 34%.
Transient exogenous expression of wild-type FAS led to
surface FAS levels of 70%. In contrast, exogenous expres-
sion of 000–220, 00800-SD1–1 (identical to 04011685) and
02M-121 mutant FAS variants showed mFAS levels of 47,
38 and 29%, respectively. Only the 20040730 mutant FAS
variant exhibited a surface FAS level similar to that of the
wild-type (64%). These results suggest that the presence of
the described mutations in FAS cDNA is sufficient for
reduced mFAS expression in the cases of T-LBLs
000–220, 00800-SD1–1 and 02M-121, but not in the case
of 20040730 (Figure 2a).
The 00800-SD1–1 variant predicted the synthesis of a
peptide truncated before the TM domain. On the other side,
the 02M-121 variant predicted the synthesis of a peptide
lacking the TM domain (sFAS). To determine whether these
peptides were secreted, an adherent cell line with proved low
endogenous expression of FAS, HEK-293T, was transfected
with the wild-type FAS or each of the variants (Figure 2b),
allowed for conditioning medium for 24 h, and assessed for
sFAS presence in cell extracts (panel 1) and extracellular
conditioned medium (panel 2) through Western blot. In the
case of the 02M-121FAS variant, but not in the case of 00800-
SD1–1, sFAS was clearly detected. This result suggested
that the 00800-SD1–1 mutant FAS might be degraded
intracellularly.
Mutant FAS variant corresponding to case 000–220
exhibits defective FAS apoptotic signaling. To assess
the functional impact of FAS mutations, each of the four
different mutant FAS variants were examined for FAS signal
triggering following transfection of JK with our pKEX
constructs (Figure 3b-d). FAS-mediated cell death was
measured as propidium iodide (PI) uptake after specific
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CH11 anti-FAS antibody treatment. CH11 antibody recog-
nizes CRD2 and CRD3 regions of FAS and is known to
recognize the same region of the death receptor than
FASLG.21 Comparisons were made against wild-type FAS
induction. Our results indicate that FAS signaling is impaired
only in the case of 000–220, which may be due to reduced
mFAS expression (as demonstrated previously, Figure 2),
combined with inefficient DISC recruitment at its DD, as
demonstrated by the impairment of caspase 8 activation
(Figure 3d). Reduced mFAS expression shown in the cases
of 00800-SD1–1 (or 04011685) and 02M-121 mutant FAS
variants, or the production of sFAS in the latter (Figure 2), do
not account for defective FAS signaling, however.
FAS expression levels are reduced in a significant
fraction of human T-LBL samples. FAS expression was
also analyzed in T-LBL samples. FAS mRNA expression
level was determined using quantitative reverse transcrip-
tion-PCR (qRT-PCR) when only RNA was available
(Figure 4) and the FAS protein level was determined using
western blot in those samples where protein extracts were
available (Figure 5). Taken together, these results indicate
that 10 out of the 26 (38.5%) human T-LBL samples
analyzed exhibited a clear reduction in the level of FAS
expression (Table 2), compared with that of the JK cell line
(proved to exhibit similar expression levels than immortalized
human thymocytes, data not shown). Among the rest of
them, FAS expression levels may vary, their reduction not
being however so remarkable. Especially interesting is the
fact that each of the human T-LBL samples already shown to
bear mutations at FAS cDNA (000–220, 00800-SD1–1,
02M-121, 20040730 and 04011685) also exhibited reduction
in FAS expression. Reduced FAS expression in 000–220,
00800-SD1–1, 02M-121 and 04011685 samples may be
explained by the sole presence of their specific mutations, as
already suggested by the in vitro expression of these mutant
variants. In contrast, the striking reduction in FAS expression
in 20040730 sample cannot be solely explained by the
occurrence of a mutation in its FAS cDNA.
Taken together, our results from the tumor samples indicate
that reduced FAS expression might be somehow contributing
to T-LBL in humans. Moreover, this mechanism may
exacerbate the effect of FAS mutations, in terms of signaling
alteration.
Altered status of the FAS signaling pathway in several
human T-LBL samples. To further determine the status of
the FAS signaling pathway in our human T-LBL samples, we
assessed the protein levels of the main members of the
pathway in the series of samples with available protein
extracts. FASLG, FADD, CASP8 and CASP3 proteins were
detected through western blot (Figure 5, Table 2).
Our results indicate that one sample (04010038) exhibited
upregulated FASLG expression, whereas it was not detect-
able in the rest of the samples. FASLG upregulation in this
sample, together with its self-protection through loss of FAS
expression, might reflect one of the mechanisms involved in
T-LBL occurrence in humans.
Figure 1 FAS mutations in T-LBL samples. Schematic representation of
mutations found in FAS in human T-LBL samples, indicating FAS exons and FAS
protein domains affected. An abbreviated form to indicate the mutations is included
and explained in the legend
Table 1 Description of FAS mutations in T-LBL samples
Sample Mutation in
DNAa
Change in protein Domain
affected
Predicted effectb Predicted effect on Fas/FasL pathwayc
#000–220 c.[290T4C;
900_901insA]
p.[Phe97Ser;
Ala301Serfs*20]
CRD2 Possibly damaging
(Score 0.632)
Interaction FAS-FASL possibly altered/
reduced mFAS expression?/Apoptosis
possibly reduced (dominant-negative effect)
DD Possibly damaging
(Score 0.922)
#00800-SD1–1 c.403_404insT p.Cys135Leufs*2 CRD3 Probably damaging
(Score 1.000)
Protein expression probably reduced/
abrogated (premature termination before
the TM4 truncated protein)
#02M-121 c.[70A4G;
506_568del]
p.[Asn24Asp;
Gly169_Trp189del]
SP Benign (Score 0.002) Isoform FASdeltaExon6 (DTM)4 soluble
protein (sFAS)4 reduced mFAS
expression
TM —
#20040730 c.418T4C p.Cys140Arg CRD3 Probably damaging
(Score 1.000)
Interaction FAS-FASL probably altered/
Reduced mFAS expression?
#04011685 c.403_404insT p.Cys135Leufs*2 CRD3 Probably damaging
(Score 1.000)
Protein expression probably reduced/
abrogated (premature termination before
the TM4 truncated protein)
The mutation at the DNA level, the change in the protein, the protein domain affected, the predicted severity of the damage and the predicted effect on the Fas
signaling are indicated.
aFrom ATG.
bBased on Polyphen-2 software.
cBased on literature21–24
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Figure 2 In vitro expression levels of mutant FAS variants. (a) JK cells transfected with wild-type or mutant FAS variant pKEX constructs. Flow cytometry showing
endogenous (shaded) and exogenous (solid) surface FAS expression levels 48 h after transfection. Figure shows a representative of three independent experiments. (b) HEK-
293T cells transfected with wild-type or mutant FAS variant pKEX constructs. Western blot of (panel 1) cellular protein extracts and (panel 2) conditioned medium protein
extracts. NTC, non-transfected control
Table 2 Overview of the alterations affecting T-LBL samples
Sample code FAS mutation FAS expression FASLG expression FADD expression CASP8 expression CASP3 expression
000–220 þ k nd nd nd nd
00800-SD1–1 þ k nd nd nd nd
02M-121 þ k nd nd nd nd
20040731 — k — k k k
20050094 — k — k k k
20040730 þ k — — — —
20041008 — k — — — —
20040734 — k — — k k
20030516 — — — k k k
20032268 — — — — — —
07010829 — — — — — —
05010346 — — — — — —
01030188 — — — k — —
02070238 — — — k — —
02050408 — — — — — —
04011685 þ k — k k k
04010460 — — — — — —
04010153 — — — — — —
11010521 — — — — — —
07010226 — — — — — —
01030192 — — — — — —
04010038 — k m — — —
46090749 — — — — — —
04100080 — — — k — —
04090135 — — — k — —
04030154 — — — — — —
Total 5/26 (19.2%) 10/26 (38.5%) 1/23 (4.3%) 8/23 (34.8%) 5/23 (21.7%) 5/23 (21.7%)
Summary of the results obtained in our TLBL sample series, concerningmutations affectingFAS, alterations of FAS expression and alterations of other members of
the Fas/FasL pathway. T-LBL cases with any of the elements altered are in bold. The percentage of each alteration type is also indicated. (þ ), mutation. ( ), normal
situation. Arrows denote altered expression. nd, not determined
Fas system deregulation in T-LBL
M Villa-Morales et al
4
Cell Death and Disease
Figure 3 Functionality of mutant FAS variants. (a) Set-up of the effective dose for CH11-mediated cell death induction, showing the normalized cell death of JK cells
treated with increasing doses of CH11. Normalization was made as follows: first, all data were divided by the result for PI staining of non-stimulated cells (0 ng/ml CH11), thus
setting the latter as 1. Second, the results for PI staining of irrelevant IgM-treated cells were subtracted from their corresponding CH11-treated cells. (b) FAS-mediated cell
death induction in JK cells transfected with wild-type or mutant FAS variant pKEX constructs. Histogram represents the mean and S.D. from at least three independent
experiments of 50 and 100 ng/ml of irrelevant IgM and CH11 induction. The percentage of PI-positive cells is showed, previously subtracting from all data the result for non-
stimulated cells. Dotted lines represent the result for % PI-positive cells treated with 50 ng/ml (black line) or 100 ng/ml (gray line) CH11 in JK cells not transfected. Significance
is indicated by the corresponding P-value. n.s., not significant. (c) Representative experiment of flow cytometry showing PI positivity 24 h after 100 ng/ml CH11-triggering by
endogenous FAS (dashed line), or exogenous wild-type (shaded) or mutant FAS variants (solid line). (d) FAS-mediated caspase 8 activation in JK cells transfected with wild-
type or mutant FAS variants pKEX constructs, 8 h after 100 ng/ml CH11-triggering. Numbers indicate fluorescence intensity corresponding to the cleaved caspase 8 staining
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FADD is essential for the apoptotic signal to be transduced
inside the cell. A clear reduction of FADD levels was found in 8
out of the 23 samples analyzed (34.8%), which suggests that
loss of FADD may be another frequent mechanism, whereby
FAS signaling would be impaired in human T-LBL samples.
CASP8 becomes active by its homotypic interaction with
FADDat theDISC complex, which in turn cleaves and activates
the effector caspase 3 (CASP3). Clearly reduced CASP8
levels, in its full-length procaspase form, were observed in 5/23
T-LBL samples (21.7%), indicating that the FASsignalingmight
as well be blocked at this step of the pathway.
Finally, a clear reduction in procaspase 3 levels were found
in the same five T-LBL samples where CASP8 was reduced
(21.7%), corroborating the blockage of FAS signaling at the
most downstream members of the pathway in these samples.
Interestingly, both the cleaved intermediate p43/p41 of
CASP8 and the large cleaved fragment p19/p17 of CASP3
were detected in one T-LBL sample (46090749), which
indicates the activation of the FAS-signaling pathway in this
sample at the precise moment of the biopsy.
In summary, these results suggest that the altered expres-
sion of members of the FAS/FASLG pathway other than FAS
may as well be involved in the occurrence of T-LBL in humans.
Discussion
Despite other cellular responses emanating from FAS
signaling (reviewed in Ehrenschwender and Wajant11), its
major and best known role is apoptotic cell death. Tumori-
genesis may be facilitated by the acquisition of resistance
towards FAS-mediated apoptosis through mechanisms
involving a variety of processes (reviewed in Villa-Morales
and Fernandez-Piqueras22). Our aim at this study was to
determine whether FAS-mediated apoptotic signaling is
compromised in human T-LBL samples and the mechanism
or mechanisms involved in such alteration.
In a 26-sample series of diagnosed T-LBL human cases, we
have found five cases (19.2%) exhibiting novel heterozygous
mutations at FAS. The functional consequences of FAS
mutations have been extensively described and they depend
on their genetics on the one side, and on the protein domain
affected on the other.23–26 Homozygous mutations usually
provoke a complete impairment of FAS-induced apoptosis
in vitro, whereas heterozygous FASmutations are related to a
partial impairment of the apoptotic system functionality.
Regarding the domain affected, mutations affecting the ECD
may cause reduced mFAS expression; mutations at the
CRD1 region of the ECD, and thus the PLAD, may result in
impaired trimerization of the FAS receptor; mutations at the
CRD2–3 regions may result in impaired interaction of FAS
receptor with the FAS ligand. This may render the affected
cells apoptosis-defective either due to a lack of multimeriza-
tion of the receptor or the lack of DISC recruitment by the
residual FAS molecules. Alterations of the TM domain, like in
the case of alternative splicing-deleting exon 6, will cause
reduced mFAS expression in the detriment of sFAS. Muta-
tions affecting the ICD may have no effect on mFAS
expression; they can exert however a transdominant-negative
effect, since trimerization between wild-type and mutant FAS
molecules takes place, but the DISC formation and the
subsequent signal transduction is not effective.
In case number 000–220, our results indicate that FAS
signaling is impaired (Figure 3), which may be the eventual
consequence of FAS mutations in this tumor, probably due to
the combination of reduced FAS expression on the surface,
impaired FAS-FASLG interaction and defective ability of the
DD at signal transduction. This could be even a dominant-
negative effect.
Case numbers 00800-SD1–1 and 04011685 exhibited the
same pointmutation affecting CRD3. Consequent reduction in
FAS expression has been demonstrated in these cases
through in vitro expression experiments, as well as in the
tumor samples (Figures 2a and 4, Table 2), and the suspicion
that the protein could be secreted was discarded (Figure 2b),
thus suggesting that this mutant FAS protein may be
degraded intracellularly. However, reducedmFAS expression
due to the sole presence of such FAS mutation does not
account for defective FAS signaling in this case, as shown in
Figure 3. Of remarkable interest, however, is the fact that
T-LBL case number 04011685 also exhibited a lack of FADD,
CASP8 and CASP3 expression, as demonstrated in the
biopsies using western blot (Figure 5, Table 2). Altogether, the
FAS pathway status of this patient seems to be abrogated at
different levels, in what might be the result of cumulative
alterations ensuring FAS resistance acquisition.
Case number 02M-121 exhibits a missense mutation at the
SP predicted to be benign. Interestingly, it also showed
alternative splicing of FAS, thus producing the sFAS protein
lacking the TM domain. This soluble protein was demon-
strated to be secreted to the extracellular medium through
in vitro expression experiments (Figure 2b). Moreover,
reduced levels of the FAS protein at the cell membrane were
found in this case (Figure 2a). The presence of sFAS in the
detriment of mFAS has been implicated in the pathogenesis of
autoimmune and malignant diseases, either by antagonizing
FASLG or by haploinsufficiency of mFAS expression.25,27,28
However, our results indicate that neither mutation-related
reduced mFAS expression nor the secretion of sFAS account
for defective FAS signaling in this case (Figure 3).
Figure 4 FAS mRNA expression level in RNA samples. qRT-PCR determining
FAS mRNA expression levels in human T-LBL samples where only RNA was
available. The mean values were normalized to that of JK. Error bars represent S.D.
Data represent two independent experiments. *Denotes statistical significance
compared with the JK control, with Po0.05
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Case number 20040730 exhibits reduced FAS expression
in the tumor sample (Figure 5, Table 2). Interestingly, this
reduction cannot be solely explained by the occurrence of a
mutation, as the in vitro mFAS expression experiments
showed a similar level to that of the wild-type sequence
(Figure 2). This suggests that regulatory mechanisms might
be responsible for the reduction of FAS expression level in the
tumor. No defective FAS signaling is detected by our in vitro
experiments in this case (Figure 3). Considering its normal
surface FAS expression, we speculate that the occurrence of
the FAS mutation described in this sample does not result in
the failure of FAS to bind its ligand either. FADD, CASP8 and
CASP3 could be detected in the biopsies using western blot,
thus suggesting that the FAS pathway might be only impaired
at the FAS expression level in this tumor.
Studies determining the molecular genetics of lymphoblas-
tic neoplasms may however suggest that FAS mutations are
not sufficient to compromise FAS function due to their low
frequency. In our study, beyond the occurrence of mutations
at the FAS gene, 10/26 (38.5%) human T-LBL samples
exhibited a clear reduction in the level of FAS expression,
which suggest that reduced FAS expression underlies the
occurrence of T-LBL to a wide extent. Reduced expression of
FAS has been recurrently reported in the literature as an
important mechanism, whereby tumor cells may resist
towards FAS-mediated apoptotic signaling. Evidence for
FAS downregulation has been shown in bladder cancer,29
primary cutaneous T-cell lymphoma,30 myeloid leukemia
cells,31 melanoma,32 colorectal carcinoma33 or breast
cancer.34 Moreover, FAS expression levels have been
determined in two independent array-based expression
profiling studies comparing T-ALL and T-LBL human samples
(GEO accession numbers GSE1577 and GSE29986). The
results show reduced FAS expression in T-LBL compared
with T-ALL, despite these differences not being significant,
probably due to the small number of samples analyzed (data
not shown).
The percentage of tumor cases showing defective FAS-
mediated apoptotic signaling is usually higher than those
bearing FASmutations or exhibiting reduced FAS expression.
Figure 5 Fas pathway expression levels in human T-LBL samples. Western blot showing FAS, FASLG, FADD, CASP8 and CASP3 protein levels in human T-LBL protein
extracts. kDa, kiloDaltons. cl, cleaved
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Thus, other mechanisms involved in FAS signaling must
underlie the impairment of those remaining cases. Several
tumors can express FASLG, necessarily together with
protective loss of FAS expression, this being considered a
mechanism by which tumors expressing FASLG escape
destruction by the immune response.12,35 In our study,
FASLG expression, together with loss of FAS, has been
detected only in one case (04010038), thus representing a
rare event in T-LBL (Table 2). The apoptotic machinery
induced by the FAS/FASLG system involves several mem-
bers whose alteration may as well result in impaired FAS
signaling. We found reduced FADD levels in 8 of the 23
samples analyzed (34.8%; Table 2), suggesting that FADD
downregulation may be another frequent mechanism
whereby FAS signaling would be impaired in human T-LBL
samples. FADD downregulation has been reported in a variety
of tumor types, such as non-small cell lung cancer,36
hepatocellular carcinoma37 or thyroid tumor.38 Caspases 8
and 3 may as well be impaired, thus resulting in FAS
resistance. In this study, we have found a clear reduction in
procaspase 8 and 3 levels in the same five T-LBL samples
(Table 2), thus indicating that the pathway might be blocked at
the most downstream members of the pathway in roughly
22% of the T-LBL cases. Taken together, these results
suggest that the altered expression of members of the FAS/
FASLG pathway other than FAS may as well be involved in
the occurrence of T-LBL in humans.
In conclusion, this study on 26 diagnosed T-LBL samples
confirms that the FAS system is impaired to a wide extent in
these tumors, with 57.7% of the cases presenting some sort of
alteration of the pathway. A variety of mechanisms seems to
be involved in such alteration: in order of frequency, the
downregulation of FAS, the deregulation of other members of
the pathway and the occurrence of mutations at the FAS-
coding sequence. Considering these results together, it
seems plausible to think of a cumulative effect of several
alterations affecting different levels of the FAS/FASLG path-
way in each T-LBL, which in turnmay result in its deregulation.
Since defective FAS signaling may render the T-LBL tumor
cells resistant to apoptotic cell death, the correct prognosis,
diagnosis and thus the success of anticancer therapy may
require such an in-depth knowledge of the complete scenario
of FAS-signaling alterations.
Materials and Methods
Human samples. Twenty-three human T-LBL samples cryo-protected in
optimal cutting temperature-embedding medium were obtained from the Spanish
Tumor Bank Network of the Spanish National Cancer Research Centre (Centro
Nacional de Investigaciones Oncologicas, CNIO, Madrid, Spain). These samples
derive from mass lesions in mediastinum or lymph nodes and are composed of
small- to medium-sized blast cells expressing nuclear terminal deoxynucleotidyl
transferase. Institutional review board approval was obtained for these studies
(references CEI 31–773, UAM Ethics Committee for Research, and RNDdT 10/
073) and the participants provided written informed consent in accordance with the
Declaration of Helsinki. RNA from three additional samples was kindly supplied by
J. Benı´tez and B. Martı´nez. Additional information is summarized in
Supplementary Table S1.
Cell culture. HEK-293T and JK cell lines were purchased from the American
Type Culture Collection (ATCC, Manassas, VA, USA). Human HEK-293T cells
were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Gibco, Life
Technologies, Carlsbad, CA, USA) with 10% FBS (PAA Laboratories, GE
Healthcare Life Sciences, Velizy-Villacoublay, France), 2 mM L-Glutamine (Merck
KGaA, Darmstadt, Germany) and sodium pyruvate (1 mM; Merck). Human JK T
cells were cultured in RPMI 1640 (Gibco) supplemented with 10% FBS (PAA
Laboratories), L-glutamine (2 mM; Merck) and 1 Minimum Essential Medium
(MEM) nonessential amino acids.
Cultures were maintained at 37 1C in a 5% CO2 humidified atmosphere.
Macromolecule extraction from human samples. Total RNA, DNA
and proteins from T-LBL human samples were extracted using TriPure Reagent
(Roche Applied Science, Indianapolis, IN, USA), following manufacturer’s
instructions. RNA extraction method was followed by AcNH4-EtOH precipitation.
FAS cDNA amplification and sequencing. Reverse transcription was
performed using SuperScript First-Strand Synthesis System for RT-PCR
(Invitrogen, Life Technologies) followed by PCR. For PCR, the Fast Start High
Fidelity PCR System (Roche Applied Science) was used, with an optimal
concentration of dimethyl sulfoxide (DMSO) of 6%. Conditions for PCR were as
indicated by the manufacturer, with an optimal annealing temperature of 57.4 1C.
Forward primer incorporated SmaI recognition site in 50 (underlined). Primer
sequences were as follows:
SmaI-Forward: 50-CCCGGGTTGGTGGACCCGCTCAGTAC-30
Reverse: 50-CCCAGTAAAAAACCAAGCAG-30
PCR products were purified using Wizard SV Gel and PCR Clean-up System
(Promega Corporation, Madison, WI, USA) and cloned into pGEM-T-Easy vector
system (Promega). Sequencing reactions of several clones from each product were
performed using an ABI Prism 310 Automated Sequencer or a 3730XL Sequencer
(Applied Biosystems, Life Technologies). All comparisons between sequences were
made using the program L-Align from ExPASy Molecular Biology Server.
Cloning of the FAS cDNA sequences. Purified DNA fragments
containing the FAS cDNA were cloned into pKEX-FAS expression plasmid (kindly
gifted by Peter Krammer, Deutsches Krebsforschungszentrum, Heidelberg,
Germany) when necessary, through consecutive digestion with SmaI and XbaI
(Roche Applied Science).
Transient transfections. HEK-293T cells were transfected using Lipofect-
AMINE Reagent (Invitrogen), following manufacturer’s instructions. JK cells were
transfected by electroporation using a Gene Pulser MXcell Electroporation System
(Bio-Rad Laboratories, Hercules, CA, USA). A total of 107 JK cells in 500ml of
complete medium were subjected to 280 V, 950mF, with 20mg of DNA.
Electroporated cells were recovered in 10ml of complete medium and analysed
48-h post transfection.
Real-time quantitative RT-PCR. The determination of the FAS transcript
levels was performed by quantification assays based on real-time qRT-PCR with a
LightCycler instrument (Roche Diagnostics GmbH, Mannheim, Germany), using
LightCycler RNA Master SYBR Green I (Roche Applied Science) and following
manufacturer’s instructions. Optimal annealing temperature was 52 1C. The gene
encoding the b2-microglobulin (b2MG) was used as an internal control of the RNA
quality and amplification. Primers were as follows:
FAS-Fw: 50-TCTTTCACTTCGGAGGATTG-30
FAS-Rv: 50-GCCTTCCAAGTTCTGAGTCT-30
b2MG-Fw: 50-CCAGCAGAGAATGGAAAGTC-30
b2MG-Rv: 50-GATGCTGCTTACATGTCTCG-30
All PCRs were repeated for each sample in two independent experiments. FAS
expression levels were calculated with the LightCycler Relative Quantification
Software (Roche Diagnostics GmbH).
Western blot. HEK-293T cells transfected with wild-type and tumor-derived
FAS pKEX constructs were assayed for exogenous FAS expression, in order to
see both the proper functionality of the constructs and the possible variations in
the expression levels among samples. Twenty-four hours after transfection, cells
were allowed for conditioning medium (without FBS) for 24 h. Then, proteins from
the conditioned medium were extracted based on acetone precipitation. Total
proteins from the cells were also obtained, using lysis buffer containing 50mM
Tris-HCl, pH 7.4; 1% NP-40; 0.25% sodium deoxycholate; 150mM NaCl; 1 mM
EGTA; 1mM PMSF; 1 mM Na3VO4; and 2.5ml/ml of Protease Inhibitor Cocktail
(Sigma-Aldrich, St. Louis, MO, USA). Thirty micrograms of cellular protein and
15ml of conditioned medium protein were electrophoresed in 10% SDS-PAGE
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without and with b-mercaptoethanol, respectively, and electrotransferred to
Immobilon-P transfer membranes (Merck Millipore, Merck).
Thirty microgram aliquots of total protein from human T-LBL samples were
separated by 10% SDS-PAGE under reducing conditions and electrotransferred to
Immobilon-P transfer membranes (Merck Millipore, Merck).
Antibodies used were as follows: anti-FAS antibody (clone CH11) (Upstate-
Merck Millipore, Lake Placid, NY, USA); anti-FADD polyclonal antibody (Santa Cruz
Biotechnology Inc., Dallas, TX, USA); anti-FASLG polyclonal antibody, anti-CASP8
antibody (clone 1C12), anti-cleaved CASP8 (D391) antibody (clone 18C8), anti-
CASP3 polyclonal antibody (all from Cell Signaling Technology Inc., Danvers, MA,
USA); anti-GAPDH antibody (clone 1D4; Enzo Life Sciences Inc., Farmingdale, NY,
USA); and the corresponding secondary antibodies: anti-mouse IgM, HRP-
conjugated (Nordic Immunology, Tilburg, The Netherlands); anti-mouse IgG, HRP-
conjugated, anti-rabbit IgG, HRP-conjugated (Cell Signaling). More information is
summarized in Supplementary Table S2.
The peroxidase activity was developed using WesternBright ECL Detection
System (Advansta Inc., Menlo Park, CA, USA).
ImageQuant LAS 4000 digital imaging system (GE Healthcare Bio-Sciences
Corp., Piscataway, NJ, USA) was used for acquisition of images.
Flow cytometry. Surface FAS expression was determined in 105 cells
preincubated with FITC labeled anti-FAS antibody, clone UB2 (MBL International,
Woburn, MA, USA) or FITC Mouse IgG1 k Isotype Control (BD Pharmingen, BD
Biosciences, San Jose, CA, USA) for 30min at room temperature. The cells
were then washed with 1 PBS containing 1% bovine serum albumin (BSA),
1 heat-inactivated FBS and 0.01% sodium azide, and analyzed by flow
cytometry on a FACSCalibur (Becton-Dickinson, Franklin Lakes, NJ, USA) for
percentage and mean fluorescence intensity.
Cleaved caspase 8 was determined by incubating cells with anti-cleaved CASP8
(D391) antibody (clone 18C8) (Cell Signaling) for 30min at room temperature, then
with Alexa Fluor 488 Donkey Anti-Rabbit IgG (Hþ L) Antibody (Molecular Probes,
Life Technologies, Carlsbad, CA, USA). Cells were then washed with 1 PBS
containing 0.5% BSA and analyzed by flow cytometry on a FACSCalibur
(Becton-Dickinson) for percentage and mean fluorescence intensity.
FAS signaling induction. Twenty-four hours after transfection (where
indicated), 2 105 JK cells at 106 cells/ml in 96-well plates were treated for
24 h (for PI staining) or 8 h (for cleaved caspase 8 staining) with anti-FAS
mouse monoclonal antibody (clone CH11; Upstate-Merck Millipore) or mouse
IgM l isotype control (clone 11E10; Beckman Coulter, Nyon, Switzerland).
Then the cells were either incubated with 2 mg/ml PI (Sigma-Aldrich) and tested
for cell death (PI positivity), or fixed and permeabilized using 4%
paraformaldehyde (Panreac Quı´mica S.L.U., Barcelona, Spain) and 90%
methanol (Merck) for cleaved caspase 8 staining, using in both cases a
FACSCalibur (Becton-Dickinson).
Software. Polyphen-2 (http://genetics.bwh.harvard.edu/pph2/) and SIFT
Human Protein (http://sift.jcvi.org/www/SIFT_enst_submit.html) softwares were
used to predict the effect of mutations on the functionality of the protein.
The FlowJo software was used for analysis after flow cytometry.
Statistical analyses. Statistical significances were determined by a
Student’s t-test, using the Statistical Package for the Social Sciences software
(SPSS version 15.0, IBM Corporation, Somers, NY, USA).
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